Salipro Biotech

Executive Summary

Salipro Biotech is a Swedish biotechnology company that has developed a proprietary platform, Salipro®, for stabilizing membrane proteins in their native conformations. Membrane proteins represent a large class of challenging drug targets, but their instability outside cellular membranes has historically hindered drug discovery. Salipro's technology overcomes this barrier, enabling the screening of small molecules and biologics against these targets. The company operates through both partnered discovery programs with pharmaceutical companies and an internal pipeline aimed at developing novel therapeutics. Founded in 2013 and based in Stockholm, Salipro has positioned itself as an enabler for tackling previously undruggable targets, particularly in areas such as cancer, metabolic diseases, and neurology. The company's platform has attracted partnerships with several major pharma firms, though specific details remain confidential. Salipro also continues to advance its own internal programs, likely focusing on high-value targets with significant unmet medical need. As a private entity, the company relies on venture capital and partnership funding to support its R&D activities. While near-term revenue is limited to upfront and milestone payments from partners, the potential for long-term value creation lies in the success of its internal pipeline. The key risk is the high attrition rate in drug discovery, but the unique capability of the Salipro platform could lead to breakthrough therapies.

Upcoming Catalysts (preview)

• Q4 2026Announcement of new pharma partnership or collaboration expansion70% success
• Q2 2027Completion of Series A or Series B financing round60% success
• Q1 2027Disclosure of preclinical data for lead internal program50% success